

# HEALTHCARE MONTHLY

OCTOBER 2020

*Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies*









BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSISIS
BioTech / Pharma			<ul style="list-style-type: none"> <li>Gilead Sciences (NasdaqGS:GILD) entered into a definitive agreement to acquire Immunomedics (NasdaqGM:IMMU)</li> <li>Immunomedics is a clinical-stage biopharmaceutical company that develops monoclonal antibody-based products for the targeted treatment of cancer</li> <li>Gilead discovers, develops and commercializes medicines in the areas of unmet medical needs</li> <li>Total consideration: \$21 billion in cash (108% premium)</li> </ul>
Healthcare Services			<ul style="list-style-type: none"> <li>Radiology Partners, a portfolio company of New Enterprise Associates and Starr Investment Holdings, entered into a securities purchase agreement to acquire MEDNAX Radiology Solutions, a division of MEDNAX, Inc. (NYSE:MD)</li> <li>MEDNAX Radiology provides radiology services nationwide through more than 300 onsite radiologists and 500 teleradiologists</li> <li>Radiology Partners is the largest physician-owned radiology practice in the U.S., serving nearly 1,300 hospitals and other healthcare facilities</li> <li>Total consideration: \$890 million in cash</li> </ul>
Life Sciences / Diagnostics			<ul style="list-style-type: none"> <li>Illumina (NasdaqGS:ILMN) entered into an agreement to acquire the remaining 85.5% stake in GRAIL</li> <li>GRAIL develops technologies for early cancer detection</li> <li>Illumina provides sequencing and array-based solutions for genetic and genomic analysis</li> <li>Total consideration: \$8 billion, consisting of \$3.5 billion in cash and \$4.5 billion in equity (33% premium)</li> </ul>
			<ul style="list-style-type: none"> <li>Patricia Industries has agreed to buy Advanced Instruments</li> <li>Advanced Instruments provides testing instruments and consumables to the clinical, biopharmaceutical and food and beverage markets</li> <li>Patricia Industries, based in Sweden, is a private equity and venture capital firm that specializes in investments in engineering, financial technology and services and healthcare sectors</li> <li>Total consideration: \$780 million in cash</li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



101% BioTech / Pharma    110% Health Services    131% Life Sci / Diagnostics    81% Medical Devices    108% S&P 500 Index

# SELECTED HEALTHCARE TRANSACTIONS


Target	Acquiror	BioTech / Pharma Transactions
OM Pharma	Optimus Holding	OM Pharma, based in Switzerland, operates as a biotechnology and pharmaceutical subcontractor, engaging in the development of synthetic and biotechnology products Total consideration: \$550 million (\$435 million in cash and up to \$115 million in milestones)
Inflazome	Roche Holding	Inflazome, based in Ireland, develops oral drugs to address unmet clinical needs in inflammatory diseases Total consideration: \$446 million in cash
Jennewein Biotechnologie	Chr. Hansen Holding	Jennewein, based in Germany, manufactures functional sugars for infant formulas and other applications Total consideration: \$363 million in cash

Target	Acquiror	Life Sci / Diagnostics Transactions
NeuMoDx Molecular	Cellink AB	NeuMoDx designs and develops molecular diagnostic solutions for hospital and clinical reference laboratories Total consideration: \$248 million in cash
Extremity Orthopedics Business of Integra LifeSciences Holdings Corporation	Yourgene Health Plc	The Extremity Orthopedics business is comprised of shoulder replacement systems, an upper and lower extremities portfolio, a sales channel, and a pipeline of new products Total consideration: \$240 million
SYNthesis med chem	Bionano Genomics	SYNthesis, based in Hong Kong, provides pharmaceutical chemistry and synthetic chemistry services to pharmaceutical and biopharmaceutical companies Total consideration: \$85 million (\$25 million in cash and up to \$60 million in milestones)

Target	Acquiror	Health Services Transactions
Simplura Health Group	The Providence Service Corporation (NasdaqGS:PRSC)	Simplura provides home health care services to patients Transaction Value: \$580 million
medipass	Inframedica	medipass, based in Italy, provides technology and management solutions for hospitals and health facilities Transaction Value: \$122 million
Community Intervention Services subsidiaries	Pathways Health and Community Support	Community Intervention Services provides community based behavioral health and substance abuse services


Target	Acquiror	Medical Device Transactions
Key Surgical	Steris (NYSE:STE)	Key Surgical manufactures disposable hospital and surgical products Total consideration: \$850 million in cash
Amplitude Surgical	PAI Partners	Amplitude Surgical develops and markets orthopedic surgery products Total consideration: \$213 million
Ascyrus Medical	CryoLife	Ascyrus develops and manufactures implantable medical devices for the treatment of aortic dissections Total consideration: \$200 million (\$60 million in cash, \$20 million in equity and up to \$120 million in milestones)

## Selected TM Capital Healthcare Experience




ULTIMED  
INCORPORATED


A PORTFOLIO COMPANY OF



LDI, Ltd.  
LAW OFFICES


HAS BEEN ACQUIRED BY AN INVESTMENT VEHICLE SUB-MANAGED BY






METRIGRAPHICS


HAS BEEN ACQUIRED BY



Cirtec  
MEDICAL


A PORTFOLIO COMPANY OF





vip-petcare


HAS BEEN ACQUIRED BY



## TM Capital's Healthcare Industry Contacts



**James McLaren,**  
Managing Director  
jmclaren@tmcapital.com  
212.809.1414



**Michael Goldman,**  
Managing Director  
mgoldman@tmcapital.com  
212.809.1419



**Paul Smolevitz,**  
Managing Director  
psmolevitz@tmcapital.com  
212.809.1416



**John Dean,**  
Vice President  
jdeen@tmcapital.com  
404.995.6234



**Steve Hunter,**  
Managing Director - Sponsor Coverage  
mgoldman@tmcapital.com  
404.995.6232